Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER vs KAON CL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Replacement of potassium in patients with hypokalemia,Prevention of hypokalemia in patients who would be at risk from developing this condition,Source of calories and fluid in parenteral nutrition when potassium supplementation is required
Treatment of hypokalemia,Prevention of hypokalemia in patients receiving digitalis and diuretics,Off-label: prevention of hypokalemia in patients on potassium-wasting diuretics
Intravenous infusion at a rate not exceeding 10 m Eq/hour (0.75 m Eq/kg/hour). Typical dose: 20-40 m Eq potassium chloride in 1 liter D5W administered over 8-12 hours.
Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
Potassium has no true elimination half-life as it is an endogenous electrolyte; redistribution half-life is approximately 1–1.5 hours for exogenous loads, reflecting cellular uptake and renal excretion. In anephric patients, half-life extends to 12–24 hours due to reliance on gastrointestinal and dialysis excretion.
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Potassium is primarily excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis and subsequent pathways to carbon dioxide and water, yielding energy.
Not significantly metabolized; primarily excreted unchanged by the kidneys, with minor fecal elimination.
Renal: >90% of potassium excreted by kidneys, with distal tubular secretion and reabsorption. Fecal: ~10% eliminated via gastrointestinal tract. Biliary: negligible.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
~10% bound to plasma proteins (albumin). Unbound fraction is physiologically active.
Minimal protein binding (<1%); not significantly bound to plasma proteins.
Total body potassium Vd ~0.5 L/kg (approximates lean body mass). For intravenously administered potassium: initial Vd approximates extracellular fluid (0.2 L/kg) with redistribution into cells over 15–30 minutes. Clinical meaning: Low Vd indicates rapid equilibration; loading doses must account for intracellular shift to avoid hyperkalemia.
Approximately 0.5–0.8 L/kg; distributes mainly in extracellular fluid, with minimal intracellular penetration.
Intravenous: 100%. Oral: ~90% (absorbed in small intestine). No other routes relevant.
Oral bioavailability is ~90-100% due to complete absorption of potassium chloride; food may slightly reduce absorption but overall high.
GFR >50 m L/min: No adjustment. GFR 30-50 m L/min: Reduce dose by 25-50%. GFR 10-30 m L/min: Reduce dose by 50-75%. GFR <10 m L/min: Avoid use or use with extreme caution; consider alternative.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: use with caution, reduce dose and monitor serum potassium; GFR < 10 m L/min: contraindicated due to risk of hyperkalemia.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50% due to risk of hyperkalemia. Child-Pugh C: Avoid use; alternative therapy recommended.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to increased risk of hyperkalemia from potential electrolyte disturbances.
Neonates and infants: 0.5-1 m Eq/kg/dose IV, not to exceed 0.5 m Eq/kg/hour. Children: 1-3 m Eq/kg/day IV, maximum infusion rate 0.5-1 m Eq/kg/hour; maximum concentration 40 m Eq/L.
Dose determined by physician based on serum potassium levels and underlying condition; typical oral dose: 1-3 m Eq/kg/day in divided doses, not to exceed 1 m Eq/kg per single dose or maximum 4 m Eq/kg/day. Extended-release tablets not recommended for children < 12 years unless specifically directed.
Start at lower end of dosing range (e.g., 10-20 m Eq per liter) and titrate slowly. Monitor renal function and serum potassium frequently. Maximum infusion rate: 5-10 m Eq/hour.
Elderly patients often have reduced renal function and may require lower starting doses (e.g., 20 m Eq twice daily) with close monitoring of serum potassium and renal function. Avoid if e GFR < 30 m L/min/1.73 m².
Potassium chloride injections are for intravenous use only. Rapid infusion may cause hyperkalemia and cardiac arrest. Concentrated potassium chloride solutions (>=2 m Eq/m L) must be diluted before use. Do not administer undiluted.
Potassium chloride can cause hyperkalemia and cardiac arrest if administered too rapidly or in excessive doses. Avoid use in patients with severe renal impairment or conditions that predispose to hyperkalemia.
Monitor serum potassium levels frequently to avoid hyperkalemia,Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Do not administer if solution is discolored or contains particulate matter,Check for compatibility with other medications in the same line
Hyperkalemia risk, especially in renal impairment,Avoid solid oral forms in patients with esophageal stricture or delayed GI transit,May exacerbate metabolic alkalosis,Monitor serum potassium levels regularly
Hyperkalemia,Severe renal impairment with oliguria or anuria,Conditions that cause potassium retention (e.g., Addison's disease, systemic acidosis),Hypersensitivity to potassium chloride or dextrose
Hyperkalemia,Severe renal impairment (oliguria, anuria, or azotemia),Concurrent use of potassium-sparing diuretics or ACE inhibitors (with caution),Untreated Addison's disease,Acute dehydration or heat cramps
Avoid excessive consumption of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados) and salt substitutes containing potassium chloride. Limit high-sodium foods as they may affect fluid and electrolyte balance.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach, potatoes) and salt substitutes containing potassium, as they may increase risk of hyperkalemia. Taking with food reduces gastrointestinal irritation.
Potassium chloride and dextrose are not teratogenic. There is no evidence of fetal harm from potassium chloride or dextrose at standard doses. Trimester-specific risks are not applicable.
Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.
Potassium chloride and dextrose are endogenous substances normally present in breast milk. No safety concerns at standard doses. M/P ratio not established; not clinically relevant as both are normal milk constituents.
Potassium is a normal component of breast milk. Exogenous potassium does not significantly alter milk levels. M/P ratio not established; considered compatible with breastfeeding.
No specific dose adjustment required for pregnancy; however, monitor for fluid overload and electrolyte imbalances due to increased plasma volume and GFR in pregnancy; adjust rate based on serum potassium and glucose.
No dose adjustment required for potassium chloride in pregnancy; pharmacokinetics are substantially unchanged.
Administer via central line if concentration exceeds 0.1% (20 m Eq/L) to avoid phlebitis. Do not exceed infusion rate of 10 m Eq/hour. Contraindicated in severe renal impairment (Cr Cl <30 m L/min), hyperkalemia, or Addison's disease. Monitor ECG for peaked T waves and serum potassium levels. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics.
KAON CL is a potassium chloride supplement. Monitor serum potassium levels frequently, especially in patients with renal impairment or those on ACE inhibitors/ARBs, NSAIDs, or potassium-sparing diuretics to avoid hyperkalemia. Administer with food to minimize gastrointestinal irritation. Do not crush or chew extended-release formulations; swallow whole. Hypomagnesemia can cause refractory hypokalemia; check magnesium levels if potassium repletion fails.
Report any signs of hyperkalemia such as muscle weakness, palpitations, or tingling sensations.,Avoid potassium-containing salt substitutes or supplements unless approved by your doctor.,This solution contains dextrose; if you have diabetes, monitor blood glucose closely.,Inform your healthcare provider about all medications, especially heart or blood pressure medicines.,Do not stop or change the infusion rate on your own.
Take this medication with a full glass of water and with food to reduce stomach upset.,Do not crush, chew, or break extended-release tablets; swallow them whole.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms of high potassium such as muscle weakness, irregular heartbeat, numbness/tingling, or confusion.,Keep all appointments for blood tests to monitor kidney function and potassium levels.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER vs KAON CL, answered by our medical review team.
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, nerve impulse transmission, cardiac muscle contractility, and skeletal muscle contraction. Dextrose provides a source of calories and may help to correct hypoglycemia.. KAON CL is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER and KAON CL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion at a rate not exceeding 10 m Eq/hour (0.75 m Eq/kg/hour). Typical dose: 20-40 m Eq potassium chloride in 1 liter D5W administered over 8-12 hours.. The standard adult dose of KAON CL is: Oral: 20 m Eq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 m Eq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER and KAON CL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not teratogenic. There is no evidence of fetal harm from potassium chloride or dextrose at standard doses. Trimester-specific risks are not appl. KAON CL is classified as Category C. Potassium chloride is not associated with teratogenicity. No increased risk of major birth defects in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.